/, Research/Long-Term Pentosan (Elmiron) Use May Be Linked to Eye Disease

Long-Term Pentosan (Elmiron) Use May Be Linked to Eye Disease

As a health publishing company dedicated to interstitial cystitis, it is our duty to share news which can impact you, the IC patient. Unfortunately, we must share some distressing news. If you have or are currently taking pentosan polysulfate PPS (brand name: Elmiron®) and are experiencing eye issues, researchers at the Emory Eye Center (Emory School of Medicine, Atlanta, GA) have now documented cases of retinal maculopathy (aka retinal injury) in SOME IC patients who have used pentosan for long periods of time. They urge patients who have used or are using pentosan to be screened by ophthalmologists if they are experiencing any unusual eye symptoms (difficulty reading, vision loss, difficulty seeing in lower lights) and to cease pentosan therapy if eye disease is present.

A Stunning Discovery

I learned about this two days ago. I was cruising through the National Library of Medicine looking for possible article ideas when I happened upon a Letter to the Editor to the Journal of Urology published on August 3, 2018 referencing an article written by J. Curtis Nickel and Robert Moldwin on the diagnostic criteria for IC research studies.(1) The ophthalmologists weren’t responding to the article, but rather were seeking an opportunity to share their concerns about an unusual presentation of eye disease that they were seeing in patients with IC who were taking pentosan polysulfate.

In a brief, three paragraph letter, they wrote “We wish to alert readers to a concerning new observation of vision threatening retinal changes associated with long-term exposure to PPS. We recently reported our findings of retinal pigmentary changes in six patients undergoing long-term therapy with PPS….Each patient had received a standard dosage of PPS, ranging from 200 to 400 mgs daily, for a median duration of 15.5 years (range 12 to 20) … Examination findings of patients with this condition are suggestive of injury to the retina and the underlying retinal pigment epithelium. After extensive investigations, which included molecular testing for hereditary retinal disease, we found these cases to resemble no other retinal disease.”(1) 

Granted, this was an unusual way to communicate with the IC community and thankfully, Moldwin and Nickel responded with concern, stating  “It is quite unlikely that urologists treating patients with IC/BPS ever would have made this association…. yet the implications are either frightening if our treatment is causing this condition or instructive if this condition is a previously unknown manifestation of IC/BPS.”(2) They noted that the Emory Eye Center has now identified more cases in their clinic as well as in the clinics of colleagues.

The Study & Data

I downloaded that original study (Pigmentary Maculopathy Associated With Chronic Exposure to Pentosan Polysulfate Sodium) to take a closer look at their findings. Published in the Journal of Ophthalmology in May 2018, it focused on six women with interstitial cystitis who presented to their clinic between May 2015 and October 2017 with pigmentary maculopathy.(3)  A maculopathy is condition which affects the center of the retina, an area associated highly sensitive and accurate vision, such as Age-Related Macular Degeneration.(4)  Most of these patients had difficulty reading and difficulty in darkness. Two patients experienced a generalized dimming of their vision as the first symptom. Two others had difficulty with near vision. One had paracentral scotomas (vision loss) in part of their eye while the other had metamorphopsia (distorted vision where straight lines become wavy).

All six patients underwent rigorous diagnostic imaging and DNA testing to determine if they had any genes associated with hereditary retinal loss. None had a family history of retinal disease nor the discovery of any pathogenic process.  What they did have in common was the use of pentosan (aka Elmiron®) for long periods of time (a median of 186 months.) Five had been treated at a dose of 400mg daily (two of whom reduced their dosage to 200mg daily after 17 years). One patient was treated with a 300mg daily dose. No other medications were used by more than 2 patients in the study.

Examinations of their eyes showed clear changes “Nearly all eyes (10 eyes of 5 patients) showed subtle parafoveal pigmented deposits at the level of the retinal pigment epithelium (RPE).” All eyes “showed subtle viteliform deposits that increased in number and extended beyond the major arcade of vessels in cases judged to be more severe. Four eyes of 2 patients showed RPE atrophy that was noted to increase in area and encroach on the central fovea over time. “ Findings were “fairly symmetrical” between the eyes of each patient. Retinal imaging also found clear diseased regions and/or atrophy though the size varied among patients.

I think it’s important to note that youngest patient in the study was just 37 years old.  Patient #4 diagnosed at the age of 23. She was taking 400mgs of Pentosan a day. She began showing visual symptoms (difficulty with near vision and difficulty reading) at the age of 30, just six years after she was diagnosed. She took Elmiron® for a total of 168 months. She had the most severe damage in the study with deep scotomas of both eyes.

Why could this be happening?

The authors suggest that the retinal cells may be accumulating PPS or a toxic metabolite over time. They express concern that “the region of affected tissue may expand over time…”  Remarkably, they point to the results of a very early Elmiron study of 2499 patients who received the drug for up to four years in which vision related adverse events were reported including: optic neuritis, amblyopia and retinal hemorrhage. (I had never seen that study nor have I seen any discussion of eye complications in Elmiron® research.)

While they say that it is to soon to conclude a definite relationship between PPS and maculopathy, they note that it is a unique presentation that does not resemble any other hereditary or acquired maculopathy. Could vision problems be a previously unrecognized effect of IC? There is no research which has demonstrated any long term connection between IC and eye health. The authors, experts in the study of rare eye diseases, said that they cannot hypothesize a pathophysiological mechanism between the IC, the bladder and/or eye health. They also state that its unusual to speculate on a  drugs toxicity 21 years after FDA approval and wonder if “perhaps chronic exposure is a requirement for development of maculopathy and we are now beginning to see patients who have met the exposure threshold to manifest a toxic maculopathy.”

They concluded with a plea for education and an urgent need for additional research. “Clinicians should be aware of this condition because it can be mistaken for other well-known macular disorders, such as pattern dystrophy and age related macular degeneration.” In their original letter to the editor they also say “We encourage drug cessation in affected patients. Furthermore, we currently recommend that any patient with suggestive visual symptoms undergo a comprehensive ophthalmic examination” 


  1. Re: FDA BRUDAC 2018 Criteria for Interstitial Cystitis/Bladder Pain Syndrome Clinical Trials: Future Direction for Research: J. C. Nickel and R. Moldwin J Urol 2018; 200: 39–42. William A. Pearce, Adam M. Hanif, Nieraj Jain  The Journal of Urology. Published online: August 3, 2018 (Just two pages)
  2. Reply by Authors.  The Journal of Urology. Published online: August 3, 2018 (Just two pages)
  3. Pigmentary Maculopathy Associated with Chronic Exposure to Pentosan Polysulfate Sodium. Pearce WA, Chen R, Jain N. Ophthalmology. 2018 May 22.
  4. Maculopathy – Wikipedia – Accessed September 1, 2018

What does this mean for you

  • Don’t Panic! Remember that information is power! Ask your doctor for copies of the articles above or visit a local medical library to find them. I’ve summarized them as best as I can but that’s no substitute for actually reading the articles. (They are copyright protected thus I’m not allowed to copy them.)
  • Seek An Eye Examination – If you have taken Elmiron® and have also developed some eye issues, out of an abundance of caution I believe that you should seek a full eye examination.
  • Educate your Urologist & Consult With Them – I encourage you to print this article out and/or reference the articles above as you talk with your urologist. Ask them to review the two very brief articles in the Journal of Urology as well as the larger article in Ophthalmology. We must spread the word!
  • Alternatives To Elmiron – The Emory Eye Center researchers encourage the cessation of pentosan if eye disease is noted.  Other bladder coating therapies are available, such as Heparin/Lidocaine instillations as well as OTC supplements CystoProtek, Cysto Renew and/or Desert Harvest Aloe. Please discuss the pros and cons with your urologist.

An Urgent Plea – Help Us Develop More Data

I’ve created a survey to help assess if the other patients might also be struggling with eye issues and/or the role that pentosan may or may not be playing in those patients.

If you have interstitial cystitis, PLEASE TAKE THIS SURVEY NOW – even if you have never used Elmiron or don’t have eye issues. This is important foundational data that could help justify a more intensive study.


By |2018-10-16T17:51:31+00:00September 1st, 2018|Interstitial Cystitis Network Blog, Research|Comments Off on Long-Term Pentosan (Elmiron) Use May Be Linked to Eye Disease

About the Author:

My Google Profile+ Jill Heidi Osborne is the president and founder of the Interstitial Cystitis Network, a health education company dedicated to interstitial cystitis, bladder pain syndrome and other pelvic pain disorders. As the editor and lead author of the ICN and the IC Optimist magazine, Jill is proud of the academic recognition that her website has achieved. The University of London rated the ICN as the top IC website for accuracy, credibility, readability and quality. (Int Urogynecol J - April 2013). Harvard Medical School rated both Medscape and the ICN as the top two websites dedicated to IC. (Urology - Sept 11). Jill currently serves on the Congressionally Directed Medical Research Panel (US Army) where she collaborates with researchers to evaluate new IC research studies for possible funding. Jill has conducted and/or collaborates on a variety of IC research studies on new therapeutics, pain care, sexuality, the use of medical marijuana, menopause and the cost of treatments, shining a light on issues that influence patient quality of life. An IC support group leader and national spokesperson for the past 20 years, she has represented the IC community on radio, TV shows, at medical conferences. She has written hundreds of articles on IC and its related conditions. With a Bachelors Degree in Pharmacology and a Masters in Psychology, Jill was named Presidential Management Intern (aka Fellowship) while in graduate school. (She was unable to earn her PhD due to the onset of her IC.) She spends the majority of her time providing WELLNESS COACHING for patients in need and developing new, internet based educational and support tools for IC patients, including the “Living with IC” video series currently on YouTube and the ICN Food List smartphone app! Jill was diagnosed with IC at the age of 32 but first showed symptoms at the age of 12.